말초동맥 질환의 최신지견
Current Knowledge of Peripheral Artery Disease
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Peripheral artery disease (PAD) is defined as atherosclerotic disease of infrarenal aorta or arteries of the lower extremities. PAD is a frequent but underdiagnosed and undertreated disease with substantial cardiovascular morbidity and mortality. Accordingly, early recognition of PAD is crucial to initiation of therapy. The ankle-brachial index (ABI) is a simple, inexpensive and noninvasive test to confirm the diagnosis of PAD and also provides risk stratification for the future cardiovascular events. Therefore, ABI should be measured in all patients with suspected PAD. Lifestyle adjustment and supervised exercise program are a major support for the therapy. Modification of treatable risk factors in conjunction with antiplatelet therapy improves cardiovascular outcomes. Cilostazol can be used as the first-line pharmacotherapy agent for the relief of claudication symptoms. Mechanical revascularization should be reserved for patients with critical limb ischemia or lifestyle limiting claudication. Remarkable technological advances in endovascular treatment have shifted revascularization strategies from traditional open surgery toward lower-morbidity percutaneous endovascular treatments. The novel therapies for increasing pain-free walking distance are under investigation. Above all, improved awareness and education in both primary physicians and the patients with cardiovascular risk factors can decrease morbidity and mortality secondary to atherosclerotic vascular disease. (Korean J Med 2011;81:444-447)
Abstract
Peripheral artery disease (PAD) is defined as atherosclerotic disease of infrarenal aorta or arteries of the lower extremities. PAD is a frequent but underdiagnosed and undertreated disease with substantial cardiovascular morbidity and mortality. Accordingly, early recognition of PAD is crucial to initiation of therapy. The ankle-brachial index (ABI) is a simple, inexpensive and noninvasive test to confirm the diagnosis of PAD and also provides risk stratification for the future cardiovascular events. Therefore, ABI should be measured in all patients with suspected PAD. Lifestyle adjustment and supervised exercise program are a major support for the therapy. Modification of treatable risk factors in conjunction with antiplatelet therapy improves cardiovascular outcomes. Cilostazol can be used as the first-line pharmacotherapy agent for the relief of claudication symptoms. Mechanical revascularization should be reserved for patients with critical limb ischemia or lifestyle limiting claudication. Remarkable technological advances in endovascular treatment have shifted revascularization strategies from traditional open surgery toward lower-morbidity percutaneous endovascular treatments. The novel therapies for increasing pain-free walking distance are under investigation. Above all, improved awareness and education in both primary physicians and the patients with cardiovascular risk factors can decrease morbidity and mortality secondary to atherosclerotic vascular disease. (Korean J Med 2011;81:444-447)
참고문헌 (15)
- Selvin E, "Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000", Circulation, 110, pp.738~743 (2004)
- Hirsch AT, "Peripheral arterial disease detection, awareness, and treatment in primary care", JAMA, 286, pp.1317~1324 (2001)
- Murabito JM, "Intermittent claudication: a risk profile from the Framingham Heart Study", Circulation, 96, pp.44~49 (1997)
- Hirsch AT, "ACC", AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery, AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation, pp.Circulation, 2006[DOI]
- Leng GC, "Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study", BMJ, 313, pp.1440~1444 (1996)
- O'Hare AM, "Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study", Circulation, 113, pp.388~393 (2006)
- Norgren L, "TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)", J Vasc Surg, 45(Suppl S), pp.S5~S67 (2007)
- Dawson DL, "A comparison of cilostazol and pentoxifylline for treating intermittent claudication", Am J Med, 109, pp.523~530 (2000)
- Thompson PD, "Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication", Am J Cardiol, 90, pp.1314~1319 (2002)
- Becker GJ, "Noncoronary angioplasty", Radiology, 170(3 Pt 2), pp.921~940 (1989)
- Schwarten DE, "Arterial occlusive disease below the knee: treatment with percutaneous transluminal angioplasty performed with low-profile catheters and steerable guide wires", Radiology, 169, pp.71~74 (1988)
- Brown KT, "Infrapopliteal angioplasty: long-term follow-up", J Vasc Interv Radiol, 4, pp.139~144 (1993)
- Feiring AJ, "Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes", J Am Coll Cardiol, 44, pp.2307~2314 (2004)
- Ko YG, "Efficacy of stent-supported subintimal angioplasty in the treatment of long iliac artery occlusions", JOURNAL OF VASCULAR SURGERY, 54(1), pp.116~122 (2011), MOSBY-ELSEVIER
- Ko YG, "Improved technical success and midterm patency with subintimal angioplasty compared to intraluminal angioplasty in long femoropopliteal occlusions", JOURNAL OF ENDOVASCULAR THERAPY, 14(3), pp.374~381 (2007)